Diarylquinolines target subunit c of mycobacterial ATP synthase
The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
The diarylquinoline R207910 (TMC207) is a promising candidate in clinical development for the treatment of tuberculosis. Though R207910-resistant mycobacteria bear mutations in ATP synthase, the compound's precise target is not known. Here we establish by genetic, biochemical and binding assays that the oligomeric subunit c (AtpE) of ATP synthase is the target of R207910. Thus targeting energy metabolism is a new, promising approach for antibacterial drug discovery.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The most promising compounds clinically, the diarylquinolines, have been shown to target the F1Fo-ATP synthase and inhibit ATP synthesis (109, 111, 112).”
From Energetics of Respiration and Oxidative Phosphorylation in Mycobacteria (2014) · cites this paper as [111]
Citations
Cites
Global Burden of Tuberculosis: Estimated Incidence, Prevalence, and Mortality by Country
Dye, C., Scheele, S., >Dolin, P., Pathania, V., Raviglione, M. C., & for the WHO Global Surveillance and Monitoring Project (1999) · JAMA · doi:10.1001/jama.282.7.677 · Cited by 2,947
A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis
Andries, K., Verhasselt, P., Guillemont, J., Göhlmann, H. W. H., Neefs, J.-M., Winkler, H., Van Gestel, J., Timmerman, P., Zhu, M., Lee, E., et al. (2005) · Science · doi:10.1126/science.1106753 · Cited by 2,191
Self-citationMolecular mechanisms that confer antibacterial drug resistance
Walsh, C. (2000) · Nature · doi:10.1038/35021219 · Cited by 1,578
The emb operon, a gene cluster of Mycobacterium tuberculosis involved in resistance to ethambutol
Telenti, A., Philipp, W. J., Sreevatsan, S., Bernasconi, C., Stockbauer, K. E., Wieles, B., Musser, J. M., & Jacobs, W. R. (1997) · Nature Medicine · doi:10.1038/nm0597-567 · Cited by 472
Telenti, A., Honoré, N., Bernasconi, C., March, J., Ortega, A., Heym, B., Takiff, H. E., & Cole, S. T. (1997) · Journal of Clinical Microbiology · doi:10.1128/jcm.35.3.719-723.1997 · Cited by 320
de Jonge, M. R., Koymans, L. H. M., Guillemont, J. E. G., Koul, A., & Andries, K. (2007) · Proteins: Structure, Function, and Bioinformatics · doi:10.1002/prot.21376 · Cited by 124
Self-citationThe F 1 F o -ATP Synthase of Mycobacterium smegmatis Is Essential for Growth
Tran, S. L., & Cook, G. M. (2005) · Journal of Bacteriology · doi:10.1128/jb.187.14.5023-5028.2005 · Cited by 116
Ji, B., Lefrançois, S., Robert, J., Chauffour, A., Truffot-Pernot, C., & Jarlier, V. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00052-06 · Cited by 107
Wang, R., Prince, J. T., & Marcotte, E. M. (2005) · Genome Research · doi:10.1101/gr.3994105 · Cited by 86
Junge, W., & Nelson, N. (2005) · Science · doi:10.1126/science.1112617 · Cited by 60
Cited by
Items 101–200 of 571
Recent developments of imidazo[1,2- a ]pyridine analogues as antituberculosis agents
Samanta, S., Kumar, S., Aratikatla, E. K., Ghorpade, S. R., & Singh, V. (2023) · RSC Medicinal Chemistry · doi:10.1039/d3md00019b · Cited by 88
A Mycobacterium tuberculosis Cytochrome bd Oxidase Mutant Is Hypersensitive to Bedaquiline
Berney, M., Hartman, T. E., & Jacobs, W. R. (2014) · mBio · doi:10.1128/mbio.01275-14 · Cited by 91
Peterson, E. J. R., Ma, S., Sherman, D. R., & Baliga, N. S. (2016) · Nature Microbiology · doi:10.1038/nmicrobiol.2016.78 · Cited by 88
Drug-resistance in Mycobacterium tuberculosis : where we stand
Mabhula, A., & Singh, V. (2019) · MedChemComm · doi:10.1039/c9md00057g · Cited by 96
Bedaquiline Targets the ε Subunit of Mycobacterial F-ATP Synthase
Kundu, S., Biuković, G., Grüber, G., & Dick, T. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01291-16 · Cited by 83
Tong, A. S. T., Choi, P. J., Blaser, A., Sutherland, H. S., Tsang, S. K. Y., Guillemont, J., Motte, M., Cooper, C. B., Andries, K., den Broeck, W. M. M. V., et al. (2017) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.7b00196 · Cited by 83
Self-citationCatalytic Asymmetric Synthesis of R207910
Saga, Y., Motoki, R., Makino, S., Shimizu, Y., Kanai, M., & Shibasaki, M. (2010) · Journal of the American Chemical Society · doi:10.1021/ja103183r · Cited by 83
Sutherland, H. S., Tong, A. S. T., Choi, P. J., Conole, D., Blaser, A., Franzblau, S. G., Cooper, C. B., Upton, A. M., Lotlikar, M. U., Denny, W. A., et al. (2018) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2018.02.026 · Cited by 82
Grant, S. S., Kawate, T., Nag, P. P., Silvis, M. R., Gordon, K., Stanley, S. A., Kazyanskaya, E., Nietupski, R. M., Golas, A. J., FitzGerald, M. G., et al. (2013) · ACS Chemical Biology · doi:10.1021/cb4004817 · Cited by 88
Novel targets in M. tuberculosis: search for new drugs
Lamichhane, G. (2010) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2010.10.004 · Cited by 96
The War against Tuberculosis: A Review of Natural Compounds and Their Derivatives
Maiolini, M., Gause, S., Taylor, J., Steakin, T., Shipp, G. M., Lamichhane, P., Deshmukh, B., Shinde, V. M., Bishayee, A., & Deshmukh, R. R. (2020) · Molecules · doi:10.3390/molecules25133011 · Cited by 85
Mycobacterium Tuberculosis: Drug Resistance and Future Perspectives
Riccardi, G., Pasca, M. R., & Buroni, S. (2009) · Future Microbiology · doi:10.2217/fmb.09.20 · Cited by 86
Chitosan nanoparticles as a promising approach for pulmonary delivery of bedaquiline
Rawal, T., Patel, S. S., & Butani, S. (2018) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2018.08.038 · Cited by 77
Current development and future prospects in chemotherapy of tuberculosis
Nuermberger, E. L., Spigelman, M., & Yew, W. W. (2010) · Respirology · doi:10.1111/j.1440-1843.2010.01775.x · Cited by 80
Chaudhari, K., Surana, S. J., Jain, P., & Patel, H. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.08.034 · Cited by 76
Foo, C. S.-Y., Lupien, A., Kienle, M., Vocat, A., Benjak, A., Sommer, R., Lamprecht, D. A., Steyn, A. J. C., Pethe, K., Piton, J., et al. (2018) · mBio · doi:10.1128/mbio.01276-18 · Cited by 78
Biuković, G., Basak, S., Manimekalai, M. S. S., Rishikesan, S., Roessle, M. W., Dick, T., Rao, S. P. S., Hunke, C., & Grüber, G. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01039-12 · Cited by 81
Upadhyay, A., Fontes, F. L., Juarrero, M. G., McNeil, M., Crans, D. C., Jackson, M., & Crick, D. C. (2015) · ACS Central Science · doi:10.1021/acscentsci.5b00212 · Cited by 86
Dookie, N., Khan, A., Padayatchi, N., & Naidoo, K. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.775030 · Cited by 72
TMC207 Becomes Bedaquiline, A New Anti-TB Drug
Palomino, J. C., & Martin, A. (2013) · Future Microbiology · doi:10.2217/fmb.13.85 · Cited by 72
Empirical ways to identify novel Bedaquiline resistance mutations in AtpE
Karmakar, M., Rodrigues, C. H. M., Holt, K. E., Dunstan, S. J., Denholm, J. T., & Ascher, D. B. (2019) · PLoS ONE · doi:10.1371/journal.pone.0217169 · Cited by 75
Torfs, E., Piller, T., Cos, P., & Cappoen, D. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20122868 · Cited by 76
Bedaquiline: A new drug approved for treatment of multidrug-resistant tuberculosis
Deoghare, S. (2013) · Indian Journal of Pharmacology · doi:10.4103/0253-7613.117765 · Cited by 71
Toogood, P. L. (2008) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2008.06.002 · Cited by 81
Huh, H. J., Kim, S., Jhun, B. W., Shin, S. J., & Koh, W. (2018) · Infection Genetics and Evolution · doi:10.1016/j.meegid.2018.10.003 · Cited by 71
Sarathy, J. P., Ragunathan, P., Shin, J. S., Cooper, C. B., Upton, A. M., Grüber, G., & Dick, T. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01191-19 · Cited by 69
Showalter, H. D., & Denny, W. A. (2008) · Tuberculosis · doi:10.1016/s1472-9792(08)70032-5 · Cited by 73
Isoniazid Bactericidal Activity Involves Electron Transport Chain Perturbation
Zeng, S., Soetaert, K., Ravon, F., Vandeput, M., Bald, D., Kauffmann, J., Mathys, V., Wattiez, R., & Fontaine, V. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01841-18 · Cited by 72
Self-citationFighting Antimicrobial Resistance: Innovative Drugs in Antibacterial Research
Süßmuth, R. D., Kulike-Koczula, M. D., Gao, P., & Kosol, S. (2025) · Angewandte Chemie International Edition · doi:10.1002/anie.202414325 · Cited by 75
Singh, S., Roy, K. K., Khan, S. R., Kashyap, V. K., Sharma, A., Jaiswal, S., Sharma, S., Krishnan, M. Y., Chaturvedi, V., Lal, J., et al. (2015) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2014.12.060 · Cited by 67
Inhibitors of energy metabolism interfere with antibiotic-induced death in mycobacteria
Lee, B. S., Kalia, N. P., Jin, X., Hasenoehrl, E., Berney, M., & Pethe, K. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.005732 · Cited by 74
Comprehensive review on mechanism of action, resistance and evolution of antimycobacterial drugs
Chauhan, A., Kumar, M., Kumar, A., & Kanchan, K. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119301 · Cited by 72
Svensson, E. M., Dooley, K. E., & Karlsson, M. O. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.03246-14 · Cited by 66
Challenges and Opportunities in Developing Novel Drugs for TB
Kaneko, T., Cooper, C. B., & Mdluli, K. E. (2011) · Future Medicinal Chemistry · doi:10.4155/fmc.11.115 · Cited by 74
Bioenergetics of Mycobacterium: An Emerging Landscape for Drug Discovery
Iqbal, I., Bajeli, S., Akela, A. K., & Kumar, A. (2018) · Pathogens · doi:10.3390/pathogens7010024 · Cited by 68
Bedaquiline inhibits the yeast and human mitochondrial ATP synthases
Luo, M., Zhou, W., Patel, H., Srivastava, A. P., Symersky, J., Bonar, M. M., Faraldo‐Gómez, J. D., Liao, M., & Mueller, D. M. (2020) · Communications Biology · doi:10.1038/s42003-020-01173-z · Cited by 67
Wang, Z., Soni, V., Marriner, G. A., Kaneko, T., Boshoff, H. I., Barry, C. E., & Rhee, K. Y. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1907946116 · Cited by 66
Yang, Q., Pan, G., Wei, J., Wang, W., Tang, Y., & Cai, Y. (2021) · ACS Sustainable Chemistry & Engineering · doi:10.1021/acssuschemeng.0c08771 · Cited by 65
Synergistic Interactions of MmpL3 Inhibitors with Antitubercular Compounds In Vitro
Li, W., Sánchez-Hidalgo, A., Jones, V. M., de Moura, V. C. N., North, E. J., & Jackson, M. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02399-16 · Cited by 70
Biological Properties of 1H-1,2,3- and 2H-1,2,3-Triazoles
da Silva, F. D. C., Cardoso, M. F. D. C., Ferreira, P. G., & Ferreira, V. F. (2014) · Topics in heterocyclic chemistry · doi:10.1007/7081_2014_124 · Cited by 75
Pediatric Tuberculosis Management: A Global Challenge or Breakthrough?
Maphalle, L. N. F., Michniak‐Kohn, B. B., Ogunrombi, M. O., & Adeleke, O. A. (2022) · Children · doi:10.3390/children9081120 · Cited by 92
Harbut, M. B., Yang, B., Liu, R., Yano, T., Vilchèze, C., Cheng, B., Lockner, J. W., Guo, H., Yu, C., Franzblau, S. G., et al. (2018) · Angewandte Chemie International Edition · doi:10.1002/anie.201800260 · Cited by 73
TBAJ-876, a 3,5-Dialkoxypyridine Analogue of Bedaquiline, Is Active against Mycobacterium abscessus
Sarathy, J. P., Ganapathy, U. S., Zimmerman, M., Dartois, V. A., Gengenbacher, M., & Dick, T. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02404-19 · Cited by 65
Ismail, N. A., Rivière, E., Limberis, J. D., Huo, S., Metcalfe, J. Z., Warren, R. M., & Rie, A. V. (2021) · The Lancet Microbe · doi:10.1016/s2666-5247(21)00175-0 · Cited by 73
Antitubercular pharmacodynamics of phenothiazines
Warman, A. J., Rito, T., Fisher, N. E., Moss, D. M., Berry, N. G., O’Neill, P. M., Ward, S. A., & Biagini, G. A. (2012) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dks483 · Cited by 71
Nakanishi‐Matsui, M., Sekiya, M., & Futai, M. (2015) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2015.11.005 · Cited by 63
Reduced susceptibility and resistance to bedaquiline in clinical M. tuberculosis isolates
Peretokina, I. V., Krylova, L. Y., Antonova, O. V., Kholina, M. S., Kulagina, E. V., Nosova, E. Y., Сафонова, С. Г., Borisov, S. E., & Zimenkov, D. V. (2020) · Journal of Infection · doi:10.1016/j.jinf.2020.01.007 · Cited by 62
Sharma, A., Rosa, M. D., Singla, N., Singh, G., Barnwal, R. P., & Pandey, A. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01833 · Cited by 64
Targeting the ATP synthase in bacterial and fungal pathogens: beyond Mycobacterium tuberculosis
Vestergaard, M. R., Bald, D., & Ingmer, H. (2022) · Journal of Global Antimicrobial Resistance · doi:10.1016/j.jgar.2022.01.026 · Cited by 65
Self-citationEmerging Drugs for Active Tuberculosis
Ginsberg, A. M. (2008) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0028-1085706 · Cited by 62
Tanwar, B., Kumar, A., Yogeeswari, P., Sriram, D., & Chakraborti, A. K. (2016) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2016.10.082 · Cited by 62
The chemical biology of new drugs in the development for tuberculosis
Barry, C. E., & Blanchard, J. S. (2010) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2010.04.008 · Cited by 68
Lü, P., Haagsma, A. C., Pham, H. L., Maaskant, J. J., Mol, S., Lill, H., & Bald, D. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00507-11 · Cited by 63
Self-citationChoi, P. J., Sutherland, H. S., Tong, A. S. T., Blaser, A., Franzblau, S. G., Cooper, C. B., Lotlikar, M. U., Upton, A. M., Guillemont, J., Motte, M., et al. (2017) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2017.10.042 · Cited by 61
Self-citationMycobacterial tuberculosis Enzyme Targets and their Inhibitors
Saxena, A. K., & Singh, A. (2019) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026619666190219105722 · Cited by 64
Lounis, N., Gevers, T., Berg, J. V. D., & Andries, K. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00566-08 · Cited by 60
Self-citationSvensson, E. M., & Karlsson, M. O. (2017) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx317 · Cited by 60
Lilienkampf, A., Pieroni, M., Wan, B., Wang, Y., Franzblau, S. G., & Kozikowski, A. P. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm901273n · Cited by 65
Wang, M.-G., Wu, S., & He, J.-Q. (2021) · BMC Infectious Diseases · doi:10.1186/s12879-021-06666-8 · Cited by 59
Kumar, S., Mehra, R., Sharma, S., Bokolia, N. P., Raina, D., Nargotra, A., Singh, P. P., & Khan, I. A. (2017) · Tuberculosis · doi:10.1016/j.tube.2017.10.008 · Cited by 57
The Role of Fatty Acid Metabolism in Drug Tolerance of Mycobacterium tuberculosis
Quinonez, C. G., Lee, J. J., Lim, J., Odell, M., Lawson, C. P. A. T., Anyogu, A., Raheem, S., & Eoh, H. (2022) · mBio · doi:10.1128/mbio.03559-21 · Cited by 62
Challenges facing the drug discovery pipeline for non-tuberculous mycobacteria
Soni, I., Groote, M. A. D., Dasgupta, A., & Chopra, S. (2015) · Journal of Medical Microbiology · doi:10.1099/jmm.0.000198 · Cited by 57
Mascolo, L., & Bald, D. (2019) · Progress in Biophysics and Molecular Biology · doi:10.1016/j.pbiomolbio.2019.11.002 · Cited by 58
Self-citationFoo, C. S.-Y., Pethe, K., & Lupien, A. (2020) · Applied Sciences · doi:10.3390/app10072339 · Cited by 61
Inhibition of M. tuberculosis and human ATP synthase by BDQ and TBAJ-587
Zhang, Y., Lai, Y., Zhou, S., Ran, T., Zhang, Y., Zhao, Z., Feng, Z., Yu, L., Xu, J., Shi, K., et al. (2024) · Nature · doi:10.1038/s41586-024-07605-8 · Cited by 60
ATP synthase superassemblies in animals and plants: Two or more are better
Seelert, H., & Dencher, N. A. (2011) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2011.05.023 · Cited by 65
Gupta, M., Subramanian, V., & Yadav, J. S. (2009) · Journal of Proteome Research · doi:10.1021/pr8009462 · Cited by 57
Pitta, E., Rogacki, M. K., Balabon, O. A., Huss, S., Cunningham, F., López-Román, E. M., Joossens, J., Augustyns, K., Ballell, L., Bates, R. H., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00245 · Cited by 54
Bioenergetic Inhibitors: Antibiotic Efficacy and Mechanisms of Action in Mycobacterium tuberculosis
Hasenoehrl, E., Wiggins, T. J., & Berney, M. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2020.611683 · Cited by 62
Tuberculosis drug discovery: Progression and future interventions in the wake of emerging resistance
Perveen, S., Kumari, D., Singh, K., & Sharma, R. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.114066 · Cited by 57
Pruksakorn, P., Arai, M., Liu, L., Moodley, P., Jacobs, W. R., & Kobayashi, M. (2011) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.34.1287 · Cited by 55
Drug targets exploited in Mycobacterium tuberculosis: Pitfalls and promises on the horizon
Bhat, Z. S., Rather, M. A., Maqbool, M., & Ahmad, Z. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.04.176 · Cited by 59
Structure-activity relationships for unit C pyridyl analogues of the tuberculosis drug bedaquiline
Blaser, A., Sutherland, H. S., Tong, A. S. T., Choi, P. J., Conole, D., Franzblau, S. G., Cooper, C. B., Upton, A. M., Lotlikar, M. U., Denny, W. A., et al. (2019) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2019.02.025 · Cited by 54
Ramírez, L. M. N., Vargas, K. Q., & Díaz, G. (2020) · Antibiotics · doi:10.3390/antibiotics9030133 · Cited by 54
Hong, W. D., Gibbons, P. D., Leung, S. C., Amewu, R. K., Stocks, P. A., Stachulski, A. V., Horta, P., Cristiano, M. L. S., Shone, A. E., Moss, D. M., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01718 · Cited by 55
Challenges in the development of drugs for the treatment of tuberculosis
Shehzad, A., Rehman, G., Ul‐Islam, M., Khattak, W. A., & Lee, Y. S. (2013) · The Brazilian Journal of Infectious Diseases · doi:10.1016/j.bjid.2012.10.009 · Cited by 55
Koch-Koerfges, A., Kabus, A., Ochrombel, I., Marin, K., & Bott, M. H. (2011) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2011.10.006 · Cited by 59
An Overview Of Tuberculosis Chemotherapy – A Literature Review
Sarkar, S., & Suresh, M. R. (2011) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.18433/j33591 · Cited by 58
He, C., Preiß, L., Wang, B., Fu, L., Wen, H., Zhang, X., Cui, H., Meier, T. W., & Yin, D. (2016) · ChemMedChem · doi:10.1002/cmdc.201600441 · Cited by 50
Ameliorating the antimicrobial resistance crisis: phage therapy
Saha, D., & Mukherjee, R. (2019) · IUBMB Life · doi:10.1002/iub.2010 · Cited by 57
Torrea, G., Coeck, N., Desmaretz, C., van de Parre, T. J. L., Poucke, T. V., Lounis, N., de Jong, B. C., & Rigouts, L. (2015) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkv117 · Cited by 49
The early bactericidal activity of antituberculosis drugs
Diacon, A. H., & Donald, P. R. (2014) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.2014.870884 · Cited by 51
New drugs for the treatment of Mycobacterium tuberculosis infection
AlMatar, M., AlMandeal, H., Var, İ., Kayar, B., & Köksal, F. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.04.105 · Cited by 53
Dual Mechanism of Action of 5-Nitro-1,10-Phenanthroline against Mycobacterium tuberculosis
Kidwai, S., Park, C.-Y., Mawatwal, S., Tiwari, P., Jung, M. G., Gosain, T. P., Kumar, P., Alland, D., Kumar, S., Bajaj, A., et al. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00969-17 · Cited by 49
Drug development against tuberculosis: Past, present and future
Vasava, M. S., Bhoi, M. N., Rathwa, S. K., Borad, M. A., Nair, S., & Patel, H. D. (2017) · Indian Journal of Tuberculosis · doi:10.1016/j.ijtb.2017.03.002 · Cited by 52
Nontuberculous Mycobacterial Resistance to Antibiotics and Disinfectants: Challenges Still Ahead
Tarashi, S., Siadat, S. D., & Fateh, A. (2022) · BioMed Research International · doi:10.1155/2022/8168750 · Cited by 54
Alderwick, L. J., Lloyd, G. S., Lloyd, A. J., Lovering, A. L., Eggeling, L., & Besra, G. S. (2010) · Glycobiology · doi:10.1093/glycob/cwq173 · Cited by 52
Speck‐Planche, A., & Cordeiro, M. N. D. S. (2013) · Current Topics in Medicinal Chemistry · doi:10.2174/15680266113139990116 · Cited by 49
Activation of type II NADH dehydrogenase by quinolinequinones mediates antitubercular cell death
Heikal, A., Hards, K., Cheung, C., Menorca, A., Timmer, M. S. M., Stocker, B. L., & Cook, G. M. (2016) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkw244 · Cited by 48
Shin, J. S., Ragunathan, P., Sundararaman, L., Nartey, W., Kundu, S., Manimekalai, M. S. S., Bogdanović, N., Dick, T., & Grüber, G. (2018) · FEBS Journal · doi:10.1111/febs.14392 · Cited by 51
Nontuberculous Mycobacteria in Cystic Fibrosis
Richards, C. J., & Olivier, K. N. (2019) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0039-1693706 · Cited by 49
Developing Pyrrole‐Derived Antimycobacterial Agents: a Rational Lead Optimization Approach
Biava, M., Porretta, G. C., Poce, G., Battilocchio, C., Alfonso, S., Logu, A. D., Manetti, F., & Botta, M. (2011) · ChemMedChem · doi:10.1002/cmdc.201000526 · Cited by 51
Ismail, N. A., Omar, S. V., Ismail, N. A., & Peters, R. P. H. (2018) · Data in Brief · doi:10.1016/j.dib.2018.09.057 · Cited by 47
Courbon, G. M., Palme, P. R., Mann, L., Richter, A., Imming, P., & Rubinstein, J. L. (2023) · The EMBO Journal · doi:10.15252/embj.2023113687 · Cited by 48
Dunn, E. A., Roxburgh, M., Larsen, L., Smith, R. A. J., McLellan, A. D., Heikal, A., Murphy, M. P., & Cook, G. M. (2014) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2014.07.050 · Cited by 53
Igarashi, M., Ishizaki, Y., & Takahashi, Y. (2017) · The Journal of Antibiotics · doi:10.1038/ja.2017.126 · Cited by 48
Albesa-Jové, D., Chiarelli, L. R., Makarov, V., Pasca, M. R., Urresti, S., Mori, G., Salina, E. G., Vocat, A., Comino, N., Mohorko, E., et al. (2014) · ACS Chemical Biology · doi:10.1021/cb500149m · Cited by 46
New treatment options for multidrug-resistant tuberculosis
Field, S. K., Fisher, D., Jarand, J. M., & Cowie, R. L. (2012) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753465812452193 · Cited by 49
A structural insight of bedaquiline for the cardiotoxicity and hepatotoxicity
Patel, H., Pawara, R. H., Pawara, K., Ahmed, F., Shirkhedkar, A. A., & Surana, S. J. (2019) · Tuberculosis · doi:10.1016/j.tube.2019.06.005 · Cited by 45
Current advances in the clinical development of anti-tubercular agents
Tetali, S. R., Kunapaeddi, E., Mailavaram, R. P., Singh, V., Borah, P., Deb, P. K., Venugopala, K. N., Hourani, W., & Tekade, R. K. (2020) · Tuberculosis · doi:10.1016/j.tube.2020.101989 · Cited by 47
Metadata
- Authors
- Koul, A., Dendouga, N., Vergauwen, K., Molenberghs, B., Vranckx, L., Willebrords, R., Ristic, Z., Lill, H., Dorange, I., Guillemont, J., Bald, D., & Andries, K.
- Affiliations
- Johnson & Johnson (United States) (US)
- Vrije Universiteit Amsterdam (NL)
- Johnson & Johnson (France) (FR)
- Corresponding author
- Koul, Anil
- Venue
- Nature Chemical Biology
- Published
- 2007-05-13
- Volume
- 3
- Issue
- 6
- Pages
- 323-324
- ISSN
- 1552-4450 (ISSN-L)
- 1552-4469
- OpenAlex
- W2093364655
- Cited by
- 547
- References
- 11
- Citations by year
- 2026: 17 · 2025: 24 · 2024: 27 · 2023: 27 · 2022: 40 · 2021: 50 · 2020: 31 · 2019: 40 · 2018: 36 · 2017: 40 · 2016: 23 · 2015: 33 · 2014: 26 · 2013: 31 · 2012: 22
- FWCI
- 6.89
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Chemical Biology (publishedVersion)
- PubMed (publishedVersion)
- VU Research Portal (publishedVersion)
- Digital Academic REpository of VU University Amsterdam (Vrije Universiteit Amsterdam) (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › ATP Synthase and ATPases Research
- Health Sciences › Medicine › Infectious Diseases › Tuberculosis Research and Epidemiology
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Bacterial Genetics and Biotechnology
- Keywords
- diarylquinolines, bedaquiline, subunit c, atpE, tuberculosis, drug target identification, drug resistance, energy metabolism, antibiotic discovery
- MeSH terms
- Antitubercular Agents, Bacterial Proteins, Binding Sites, Kinetics, Quinolines, Electrophoresis, Gel, Two-Dimensional, Mycobacterium smegmatis, Protein Subunits, ATP Synthetase Complexes, Bacterial Proton-Translocating ATPases, Diarylquinolines
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.